Amphastar Pharmaceuticals Inc. share price logo

Amphastar Pharmaceuticals Inc.

NASDAQ: AMPH

Small Cap

$20.10

-0.08

(-0.40%)

as on

Amphastar Pharmaceuticals Inc. Stock Performance

as on July 2, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $19.91
    $20.54
    downward going graph

    0.95%

    Downside

    2.19%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $16.65
    $31.26
    downward going graph

    17.19%

    Downside

    55.54%

    Upside

    downward going graph

Amphastar Pharmaceuticals Inc. share price movements today

Previous Close
$20.18
Open
$20.32
Volume
810.8K
Day's Low - High
$19.91 - $20.54
52 Week Low - High
$16.65 - $31.26

Amphastar Pharmaceuticals Inc. Historical Returns

1 Month Return
+ 9.55 %
3 Month Return
-0.3 %
1 Year Return
-13.54 %
3 Year Return
-64.89 %
5 Year Return
-1.27 %

Amphastar Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Amphastar Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$960.3M

EPS (TTM)

2.6804

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.72%

PE Ratio (TTM)

13.12

Industry PE ratio

-3.111470588235294

PEG Ratio

2.77

EBITDA

197.3M

Revenue (TTM)

720.5M

Profit Margin

11.00%

Return On Equity TTM

10.39%

Amphastar Pharmaceuticals Inc. Stock Valuation

Track how Amphastar Pharmaceuticals Inc. P/E has moved over time to understand its valuation trends.

Amphastar Pharmaceuticals Inc. in the last 5 years

  • Overview

  • Trends

Lowest (7.36x)

June 30, 2025

Industry (-3.11x)

July 1, 2026

Today (13.12x)

July 1, 2026

Highest (20.48x)

June 30, 2022

LowHigh

Today’s Price to Earnings Ratio: 13.12x

Amphastar Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Amphastar Pharmaceuticals Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$960.3M-1.27%13.1211.00%NA
BUY$23.0B193.4%20.0540.62%NA
HOLD$18.9B7.66%NA-2.04%2.94%
BUY$41.1BNA19.0415.11%2.07%
BUY$31.9B-62.04%12.4728.04%2.6100000000000003%

Stock Returns calculator for Amphastar Pharmaceuticals Inc. Stock including INR - Dollar returns

The Amphastar Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Amphastar Pharmaceuticals Inc. investment value today

Current value as on today

₹95,791

Returns

-₹4,209

(-4.21%)

Returns from Amphastar Pharmaceuticals Inc. Stock

-₹13,882 (-13.88%)

Dollar Impact

₹9,672 (+9.67%)

Analyst Recommendation on Amphastar Pharmaceuticals Inc. Stock

Based on 12 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 12 analysts, 75% of analysts recommend a 'BUY' rating for Amphastar Pharmaceuticals Inc.. Average target price of $22.83

Amphastar Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Amphastar Pharmaceuticals Inc..

What analysts predicted

11.96%UPSIDE

Target Price

$22.83

Current Price

$20.1

Analyzed by

12 Analysts

Target

$22.83

Amphastar Pharmaceuticals Inc. target price $22.83, a slight upside of 11.96% compared to current price of $20.1. According to 12 analysts rating.

Indian Investors' Interest in Amphastar Pharmaceuticals Inc. Stock

Search interest for Amphastar Pharmaceuticals Inc. Stock has increased by 19% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:19% versus previous 30 day period

Amphastar Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
178
171
182
188
186
170
174
191
183
171
Gross Profit
96
87
95
101
86
85
86
98
85
70
Operating Income
53
48
55
57
45
37
42
25
35
13
EBITDA
64
69
72
68
65
52
61
41
54
33
Interest Expense
9
8
8
6
6
6
6
6
6
6
Depreciation
13
13
14
14
14
15
16
15
15
16
Income Before Tax
40
47
50
47
43
30
39
21
31
10
Income Tax Expense
4
4
12
7
5
5
8
4
7
3
Net Income
36
43
37
40
37
25
31
17
24
6
Net Profit Margin
20.31%
25.13%
20.81%
21.41%
20.35%
14.83%
17.79%
9.04%
13.34%
3.75%

Amphastar Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
255
240
294
322
349
437
498
644
731
719
Gross Profit
104
90
106
131
143
199
248
351
373
356
Operating Income
15
0
-8
0
10
69
107
196
205
140
EBITDA
30
11
7
21
30
111
146
240
277
212
Interest Expense
1
0
0
0
0
0
1
27
30
25
Depreciation
-
15
16
21
25
26
28
35
57
63
Income Before Tax
14
1
-9
60
4
83
114
169
189
123
Income Tax Expense
4
-2
-3
13
3
20
23
31
29
25
Net Income
10
4
-5
48
1
62
91
137
159
98
Net Profit Margin
4.13%
1.88%
-1.95%
15.18%
0.40%
14.19%
18.31%
21.34%
21.79%
13.63%

Amphastar Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
43
37
40
37
25
31
17
24
6
Operating Cash Flow
55
69
59
29
35
35
52
32
47
Investing Cash Flow
15
-69
-34
-35
10
0
-19
-60
-16
Financing Cash Flow
-13
-10
-22
-33
-14
-30
-4
-18
-30
Change in Cash
56
-11
2
-40
31
4
28
-46
0

Amphastar Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4
-6
46
1
63
91
137
159
98
Operating Cash Flow
39
38
41
57
97
89
183
213
156
Investing Cash Flow
-38
-42
-50
-36
-28
-32
-649
-124
-70
Financing Cash Flow
-7
25
-3
-2
-37
-26
454
-80
-67
Change in Cash
-6
20
-12
18
32
29
-11
7
18

Global Institutional Holdings in Amphastar Pharmaceuticals Inc.

Funds
Holdings
UBS Group AG
0.95%
State Street Corp
3.65%
Vanguard Capital Management, LLC
3.5%
Northern Trust Corp
0.84%
Arrowstreet Capital Limited Partnership
1.25%

Insights on Amphastar Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AMPH has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, SANDOZ GROUP AG SPONSORED ADS Switzerland has given 101.3% return, outperforming this stock by 116.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 24.42M → 6.42M (in $), with an average decrease of 73.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, AMPH stock has moved down by -4.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 191.84M → 171.17M (in $), with an average decrease of 5.5% per quarter

About Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
OrganisationAmphastar Pharmaceuticals Inc.
Headquarters11570 6th Street, Rancho Cucamonga, CA, United States, 91730
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Yongfeng Zhang Ph.D.
E-voting on sharesClick here to vote

Key Management of Amphastar Pharmaceuticals Inc.

Name

Title

Tony Marrs M.B.A., M.P.H., M.S.

Executive VP of Regulatory Affairs & Clinical Operations

Dr. Ziping Luo Ph.D.

Chairman of the Board, Chief Scientist & COO

Dr. Yongfeng Zhang Ph.D.

Co-Founder, President, CEO, Chief Scientific Officer & Director

Mr. William J. Peters M.B.A.

CFO, Executive VP of Finance, Treasurer & Director

Mr. Jacob Liawatidewi M.B.A.

Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director

Mr. Rong Zhou M.S.

Senior EVP of Production & EVP of Scientific Affairs

Mr. Dan Dischner M.B.A.

Senior Vice President of Human Resources & Corporate Communication

FAQs

What is Amphastar Pharmaceuticals Inc. share price today?

Amphastar Pharmaceuticals Inc. share price today is $20.1 as on at the close of the market. Amphastar Pharmaceuticals Inc. share today touched a day high of $20.54 and a low of $19.91.

What is the 52 week high and 52 week low for Amphastar Pharmaceuticals Inc. share?

Amphastar Pharmaceuticals Inc. share touched a 52 week high of $31.26 on and a 52 week low of $16.65 on . Amphastar Pharmaceuticals Inc. stock price today i.e. is closed at $20.1,which is 35.71% down from its 52 week high and 20.76% up from its 52 week low.

What is Amphastar Pharmaceuticals Inc.'s market capitalisation today?

Amphastar Pharmaceuticals Inc. market capitalisation is $0.00T as on .

How to invest in Amphastar Pharmaceuticals Inc. Stock (AMPH) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Amphastar Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amphastar Pharmaceuticals Inc. Shares that will get you 0.0746 shares as per Amphastar Pharmaceuticals Inc. share price of $20.1 per share as on July 2, 2026 at 8:45 am IST.

What is the minimum amount required to buy Amphastar Pharmaceuticals Inc. Stock (AMPH) from India?

Indian investors can start investing in Amphastar Pharmaceuticals Inc. (AMPH) shares with as little as ₹95.2475 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.48 in Amphastar Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Amphastar Pharmaceuticals Inc. share’s latest price of $20.1 as on July 2, 2026 at 8:45 am IST, you will get 0.4975 shares of Amphastar Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Amphastar Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Amphastar Pharmaceuticals Inc. stock has given -1.27% share price returns and 26.8% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?